Scientists Develop a Gene-Based Mouth Swab That Detects Oral Cancer in Under an Hour

Oral cancer is becoming more common worldwide, yet it often goes undetected until advanced stages. Early diagnosis is crucial, but current methods can be invasive, slow, and uncomfortable for patients. A new test developed by researchers in the United Kingdom and India could help address these challenges.

Scientists have developed a non-invasive oral swab test that can identify early-stage oral cancer with high accuracy in less than an hour. The approach is designed to be fast, repeatable, and significantly less invasive than traditional surgical biopsies, potentially improving both diagnosis and long-term monitoring.

How the New Swab Test Works

The quantitative Malignancy Index Diagnostic System, or qMIDS, uses a brush biopsy collected from a suspicious lesion inside the mouth. Clinicians gently swab the affected area to collect superficial cells, which are then analyzed for specific patterns of gene activity associated with oral cancer.

The test measures the expression of four genes linked to malignant transformation. A second swab is taken from a healthy area of the mouth to serve as a control. By comparing the two samples, the system calculates a malignancy index score that helps distinguish benign lesions from cancerous or high-risk tissue.

High Accuracy in a Large Patient Study

Earlier versions of qMIDS had already shown promising results, prompting researchers to refine the technology and evaluate it in a larger clinical study. In the latest trial, brush biopsies were collected from 545 patients with potentially pre-cancerous or cancerous oral lesions at clinics in the United Kingdom and India.

The third-generation qMIDS test achieved an overall accuracy of 95.5% in distinguishing oral cancer from non-cancerous lesions. Both false-positive and false-negative rates were below 5%, making its performance comparable to minimally invasive tissue biopsies.

Results were available in approximately one hour, representing a substantial improvement over conventional histopathology, which often requires several days. According to the researchers, the strong gene-expression signals detected in superficial cells explain why a simple brush swab can provide results comparable to more invasive sampling techniques.

Benefits for Patients and Clinicians

Conventional diagnosis typically requires removing a small piece of tissue with a scalpel for laboratory analysis. This procedure can be uncomfortable, particularly when lesions are located on sensitive areas such as the tongue, gums, or inner cheek, and it may need to be repeated to monitor suspicious changes over time.

Because of this discomfort, some patients may delay or decline follow-up biopsies, increasing the risk that malignant changes remain undetected. The qMIDS brush test offers a less invasive alternative that can be repeated more easily, allowing clinicians to monitor suspicious lesions over time and intervene earlier if cancer develops.

The test could also help prioritize patients with high-risk lesions for specialist assessment while reducing unnecessary procedures and anxiety among those with benign findings by providing faster diagnostic information.

The Rising Global Burden of Oral Cancer

The global number of oral cancer cases has more than doubled since 1990, while mortality has also increased. Major risk factors include tobacco use, heavy alcohol consumption, high consumption of sugary drinks, and infection with human papillomavirus, particularly HPV type 16.

Early oral cancers often appear as persistent sores, white or red patches, or subtle changes in the lining of the mouth. Because these symptoms can resemble minor injuries or harmless conditions, they are frequently overlooked, especially in areas with limited access to specialist care.

Researchers suggest that rapid and relatively affordable diagnostic tools such as qMIDS could be particularly valuable in low-resource settings, where delayed diagnosis and limited pathology services contribute to poorer outcomes. Providing results during the same visit could help reduce delays in treatment.

Next Steps Toward Clinical Use

The findings, published in Biomarker Research, support further development and regulatory evaluation of the qMIDS platform. The research team is collaborating with commercial partners to scale up the technology and adapt it for routine use in dental practices and specialist clinics.

The researchers estimate that, pending regulatory approvals and additional validation studies, the test could become available for clinical use within approximately two years. They also believe that similar gene-expression-based swab tests could eventually be adapted for other head and neck cancers and high-risk pre-cancerous conditions.

Although further research is needed to confirm the test's performance across broader populations and healthcare settings, the study adds to growing evidence that minimally invasive molecular diagnostics may improve how cancers are detected and monitored. For many patients, this could eventually mean replacing a surgical biopsy with a quick and painless swab.